Flag of the European Union EU Clinical Trials Register Help

Legal notice

  1. The protocol related information on clinical trials conducted in the EEA is shown as supplied by the sponsors and loaded into the database by the national competent authorities (NCAs). The NCAs review the clinical trial application and add their authorisation and the ethics committee's opinion, and complete the end-of-trial information. The protocol related information on third-country clinical trials is supplied by paediatric-investigation-plan (PIP) addressees or their agents. The European Medicines Agency (EMA) is not responsible for the completeness or accuracy of this information. In addition, the EMA and NCAs assume no liability for any party's use, or the results of such use, of any part of the database.
  2. The result related information on clinical trials conducted in the EEA and/or outside of the EEA is shown as posted into EudraCT by the sponsor/MAH/PIP addressee. The European Medicines Agency (EMA) is not responsible for the completeness or accuracy of this information. In addition, the EMA and NCAs assume no liability for any party's use, or the results of such use, of any part of the database.
  3. Publication of protocol and results related information on a clinical trial in the EU Clinical Trials Register does not in itself constitute an authorisation of that trial, nor an endorsement of the scientific, clinical or ethical aspects of the trial or of the information presented. In case of discrepancy between the information published in the EU Clinical Trials Register on the one hand and the NCA decision and/or ethics committee’s opinion on the other hand, the latter will prevail. The information published should not be used as a recommendation to use the medicine or to participate in the trial. A healthcare professional should be consulted to discuss appropriate treatment options.
  4. Information on clinical trials entered into the database between 1 May 2004 and the release of EudraCT Version 8.0 on 10 March 2011 is historical data, and may be incomplete or inconsistent. For instance, the end-date of a trial may not have been recorded, so the trial may appear to be ongoing when it has in fact been completed.
  5. The information displayed is the most recent information added to EudraCT. This may not reflect the current status of the protocol because only certain substantial amendments are required to be notified to the Member States.
  6. The NCAs and the EMA are working to develop, where possible, a more complete data set for historical trials. They are also working to improve the quality of new records through enhanced automated checking and quality-control from 10 March 2011 onwards, and through the increased use of standard terminology lists, where possible, instead of free text.
  7. In any publication or distribution of these data, you should attribute the source as 'EU Clinical Trials Register', and clearly display the date the data were accessed.
  8. E-mail addresses extracted from the EU Clinical Trials Register must not be used for marketing or other promotional purposes.
  9. The information presented on third-country clinical trials that form part of a PIP is made public with the content provided by the PIP Addressee or their agent, and has not been subject to regulatory review by either the European Medicines Agency or the National Competent Authorities of the EEA.
  10. For copyright information, refer to the European Medicines Agency copyright and limited reproduction notices External link.

Version of the website

EU Clinical Trials Register version 2.2

 

See also:

Glossary PDF document

How to search PDF document

FAQs PDF document

Patients’ and Consumers’ Organisations’ contact information PDF document

Healthcare Professionals’ Organisations contact information PDF document

Sponsors' contact information PDF document

For technical support, visit the EMA Service Desk portal
European Medicines Agency © 1995-2017 | 30 Churchill Place, Canary Wharf, London E14 5EU
Legal notice
EMA and HMA